The prognostic potential of alkaline phosphatase and lactic acid dehydrogenase in bmCRPC patients without significant PSA response under enzalutamide

Abstract Background In patients with bone metastatic castration-resistant prostate cancer (bmCRPC) on systemic treatment, it is difficult to differentiate between continuous rise of prostate specific antigen (PSA) representing progression, and PSA-surge, which is followed by clinical response or sta...

Full description

Bibliographic Details
Main Authors: Renata Poteska, Kambiz Rahbar, Axel Semjonow, Andres Jan Schrader, Martin Boegemann, Katrin Schlack
Format: Article
Language:English
Published: BMC 2022-04-01
Series:BMC Cancer
Subjects:
Online Access:https://doi.org/10.1186/s12885-022-09483-7